ARS Pharmaceuticals, Inc.
SPRYARS Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of needle-free intranasal epinephrine delivery systems.
Earnings
Next report
Nov 9, 2026 (in 2 months)Valuation & ratios
Segments
By geography
Competitors
By market cap
By revenue growth
By net margin
Profile
ARS Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of needle-free intranasal epinephrine delivery systems. Its lead product, neffy, provides a non-invasive alternative to traditional injectable treatments for Type I allergic reactions, including anaphylaxis. The company aims to address unmet needs in the allergy market by improving patient compliance and reducing the needle-related anxiety associated with emergency epinephrine administration.
ARS Pharmaceuticals holds a first-mover advantage as the provider of the first and only FDA-approved needle-free epinephrine product, challenging a decades-old reliance on injectable delivery methods.
FAQ
- What is ARS Pharmaceuticals, Inc.'s market cap?
- ARS Pharmaceuticals, Inc. (SPRY) has a market capitalization of $414.2M and trades on NASDAQ.
- What is ARS Pharmaceuticals, Inc.'s revenue and profitability?
- ARS Pharmaceuticals, Inc. generated $116.9M in trailing twelve-month revenue with a net loss of $215.4M, representing a net margin of -184.2%, with free cash flow of -$196.6M. The latest reported period is Q2 2026.
- Who are ARS Pharmaceuticals, Inc.'s competitors?
- ARS Pharmaceuticals, Inc.'s key competitors include Amneal Pharmaceuticals, Viatris Inc., Aquestive Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does ARS Pharmaceuticals, Inc. partner with?
- ARS Pharmaceuticals, Inc.'s notable partners include ALK-Abelló, Alfresa Holdings, CSL Seqirus, and others.
- Where is ARS Pharmaceuticals, Inc. headquartered?
- ARS Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 24 people. It has been publicly traded since 2022.
